Latest Kidney Cancer News

Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population

Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) – Scientific Reports

Thermal Ablation vs Surgery for Stage T1a RCC Offers Similar Cancer-Specific Survival – Oncology Nurse Advisor
Kidney Cancer News elsewhere on the Web

Panelists discuss how the KEYNOTE-426 trial established pembrolizumab plus axitinib as an effective and well-tolerated immunotherapy-tyrosine kinase inhibitor (IO-TKI) combination with high response rates and unprecedented tumor control, particularly suitable for frail patients due to ...

There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The ...

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

The combination also yielded durable responses in a subset of patients with sporadic papillary renal cell carcinoma.

Hong Truong, MD, MS, details key findings on referrals for genetic counseling among patients with kidney cancer who meet the criteria for genetic evaluation.

Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.

Panelists discuss how the CheckMate 214 study demonstrated durable overall survival benefits with ipilimumab plus nivolumab vs sunitinib, with 9-year follow-up showing improved outcomes even in favorable-risk patients and nearly half of responders remaining in remission.

Panelists discuss how clear cell renal cell carcinoma (RCC) represents the most common kidney cancer subtype, typically affecting men in their 50s and 60s who often present incidentally with metastatic disease, and has limited identifiable risk factors beyond smoking, hypertension, and obesity.

In a groundbreaking leap forward for cancer immunotherapy, researchers at UCLA have engineered a novel cell therapy designed to confront one of the most stubborn and deadly cancers: metastatic renal

Boris M. Kiselev, MD, provides practical advice for oncology clinicians on how to approach and initiate conversations about a patient’s mental and emotional well-being.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.





